Enovis (NYSE:ENOV) Updates FY 2025 Earnings Guidance

Key Points

• Enovis issued updated FY 2025 earnings guidance, projecting EPS between 3.050-3.200 and revenue of $2.2 billion-$2.3 billion, slightly exceeding consensus estimates.
• Several analysts have recently downgraded their price targets for Enovis, with Canaccord Genuity reducing their target from $75.00 to $70.00, while Needham lowered theirs from $64.00 to $57.00.
• Institutional investors hold 98.45% of Enovis's stock, indicating strong institutional interest, with Goldman Sachs increasing their stake by 37.6%.

Enovis (NYSE:ENOV - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.050-3.200 for the period, compared to the consensus earnings per share estimate of 3.028. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion.

Wall Street Analyst Weigh In

ENOV has been the topic of several recent research reports. UBS Group cut their price objective on shares of Enovis from $65.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday. Canaccord Genuity Group decreased their target price on shares of Enovis from $70.00 to $58.00 and set a "buy" rating for the company in a research report on Friday. Evercore ISI cut their price target on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Needham & Company LLC reduced their price target on shares of Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Wells Fargo & Company lowered their price objective on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research report on Friday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $51.00.

Enovis Price Performance

Shares of ENOV stock traded down $0.18 during trading on Monday, hitting $28.26. The company had a trading volume of 502,606 shares, compared to its average volume of 1,199,226. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The stock's 50-day moving average is $30.54 and its two-hundred day moving average is $35.14. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -1.98 and a beta of 1.70. Enovis has a 52 week low of $25.47 and a 52 week high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.79 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.05. The company had revenue of $564.50 million during the quarter, compared to analyst estimates of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. The firm's revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. As a group, analysts predict that Enovis will post 2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its stake in shares of Enovis by 37.6% in the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company's stock valued at $10,226,000 after acquiring an additional 73,116 shares during the period. AQR Capital Management LLC grew its stake in shares of Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company's stock worth $2,363,000 after acquiring an additional 7,072 shares during the last quarter. Finally, Empowered Funds LLC grew its stake in shares of Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock worth $249,000 after acquiring an additional 749 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.